Esteva, F.J., Rosoles, M.F., Esparazaguerre, L.T., Sahin, A.A., Soss, M.I., Booser, D.J., et al. (2000) Phase II Trial of Primary Chemotherapy with Docetaxel and Doxorubicin in Locally Advanced Breast Cancer-Clinical and Pathological Results. 36th Annual Meeting on Program/Proceedings of the American Society of Clinical Oncology, Vol. 19, May 2000.

has been cited by the following article:

• TITLE: Primary Surgery Compared to Post Chemotherapy Surgery for Patients with Locally Advanced Breast Cancer

  AUTHORS: Ibrahim Altedlawi AlBalawi

  KEYWORDS: Adjuvant, Breast, Cancer, Neoadjuvant, Surgery

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.10, October 8, 2018

  ABSTRACT: Purpose: To compare primary surgery and surgery after neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (LABC) patients. Methods: Between January 2011 & December 2015, 112 patients with LABC were treated at KAAH & OC-Jeddah-KSA, Of whom 42 were treated by NCT followed by surgery either mastectomy or conservative surgery, then adjuvant chemotherapy and radiotherapy. The rest patients (70) were treated by primary surgery (mastectomy or conservative resection) and followed by adjuvant chemotherapy and radiotherapy. All patients received adjuvant antiestrogen. Patients were followed for a median duration of 33 months. Disease-free survival (DFS) and overall survival (OAS) were studied for all patients, compared between both groups and related to the extent of surgery and menopausal status. Results: median age was 46.5 years for all patients; 48 years, and 46 years for NCT and primary surgery groups respectively. Median DFS was 15 months for all patients, 16 & 15 months for NCT and primary surgery groups. Median OAS was 24 months for all patients, 22 & 24 months for NCT and primary surgery groups. Difference in DFS & OAS were highly significant in favour of postmenopausal patients (p = 0.05 for DFS & p = 0.03 for OAS) while in primary surgery group the differences between pre and postmenopausal patients in DFS & OAS were statistically insignificant (p = 0.4). NCT followed by surgery group patients showed significant improvement in DFS & OAS in patients performed conservative surgery while in primary surgery group the difference was insignificant. Freedom of disease was seen in 28.6% in the NCT group and 37.1% for the primary surgery group. Conclusion: Surgery post-neoadjuvant chemotherapy neither prolongs DFS nor OAS in comparison with primary surgery followed by adjuvant chemotherapy. Postmenopausal patients felt much better than premenopausal patients regarding DFS & OAS.